Results of the Annual General Shareholder Meeting as of June 13, 2023Antoine Balavoine2023-06-14T23:59:46+02:00June 15th, 2023|
Description of the share buyback program authorized by the Combined General Meeting of June 13, 2023Antoine Balavoine2023-06-14T23:45:53+02:00June 15th, 2023|
Pixium Vision announces receipt of € 1.8 million from the French Government as Research Tax CreditAntoine Balavoine2023-06-08T07:51:22+02:00June 8th, 2023|
Annual Meeting of Shareholders June 13, 2023 – Availability of preparatory documentsAntoine Balavoine2023-05-24T19:12:39+02:00May 24th, 2023|
Pixium Vision convenes its Annual Meeting of Shareholders on June 13, 2023Antoine Balavoine2023-05-10T18:57:07+02:00May 10th, 2023|
Pixium Vision announces the availability of its annual report for the financial year 2022Antoine Balavoine2023-04-25T20:27:12+02:00April 25th, 2023|
Pixium Vision announces its consolidated financial statements for the financial year 2022 and the consolidated cash balance for March 31, 2023Antoine Balavoine2023-04-21T02:33:53+02:00April 21st, 2023|
Communication following the announcement of FDA Breakthrough Device Designation for the Prima System in Dry AMDAntoine Balavoine2023-04-03T00:00:46+02:00April 3rd, 2023|
Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMDAntoine Balavoine2023-03-31T11:13:27+02:00March 31st, 2023|
Reduction of share capital due to losses by reduction of nominal value: number of shares unchangedAntoine Balavoine2023-03-17T08:49:29+01:00March 17th, 2023|
Extraordinary Shareholder Meeting of March 8, 2023: Notice of publication of the preparatory documentsLino Talfer2023-03-01T14:11:04+01:00February 28th, 2023|
Second convening of the Extraordinary Shareholder Meeting on March 8, 2023Antoine Balavoine2023-02-16T20:37:35+01:00February 16th, 2023|
Pixium Vision announces its cash position at 31 December 2022 and provides an update on its activitiesAntoine Balavoine2023-02-14T22:40:31+01:00February 14th, 2023|
